Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity

Clinical Infectious Diseases

Volumn 30, Issue 2, 2000, Pages 313-318

  Falloon, Judith ^a   Piscitelli, Stephen ^b   Vogel, Susan ^a   Sadler, Brian ^d   Mitsuya, Hiroaki ^c   Kavlick, Mark F ^c   Yoshimura, Kazuhisa ^c   Rogers, Michael ^d   LaFon, Steven ^d   Manion, Douglas J ^e   Lane, H Clifford ^a   Masur, Henry ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d GLAXOSMITHKLINE   (United States)

^e DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; EFAVIRENZ; INDINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PARESTHESIA; PRIORITY JOURNAL; TREATMENT FAILURE;

ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; BASE SEQUENCE; CARBAMATES; DIDEOXYNUCLEOSIDES; DRUG INTERACTIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; OXAZINES; PHENOTYPE; PILOT PROJECTS; RNA, VIRAL; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0034011272     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313667     Document Type: Article

References (19)

1. 1. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998; 47(RR-5):43-82.
2. 2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl J Med 1998; 338:853-60.
3. 3. Volberding PA, Decks SG. Antiretroviral therapy for HIV infection: promises and problems. JAMA 1998; 279:1343-4.
4. 4. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353:863-8.
5. 5. Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science 1998; 280:1871-3.
6. 6. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 1998; 279:1984-91.
7. 7. Woolf E, Au T, Haddix H, Matuszewski B. Determination of L-735.524. a human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching. J Chromatogr A 1995; 692:45-52.
8. 8. Theoretical Biology and Biophysics Group T-10. Human retroviruses and AIDS: a compilation and analysis of nucleic acid and amino acid sequences, Los Alamos, NM: Los Alamos National Laboratory, 1995.
9. 9. Shirasaka T, Yarchoan R, O'Brien MC, et al. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci USA 1993; 90:562-6.
10. 10. Yoshimura K, Kato R, Yusa K. et al. JE-2147: a dipeptide protease inhibitor (P1) that potently inhibits multi-PI resistant HIV-1. Proc Natl Acad Sci USA 1999; 96:8675-80.
11. 11. Shirasaka T, Kavlick MF, Ueno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995; 92:2398-402.
12. 12. Tanaka M, Srinivas RV, Ueno T, et al. In vitro induction of human immunodeficiency virus type 1 variants resistant to 2′-beta-fluoro-2′,3′-dideoxyadenosine. Antimicrob Agents Chemother 1997; 41:1313-8.
13. 13. Acosta EP, Henry K, Weller D, et al. Indinavir pharmacokinetics and relationships between exposure and antiviral effect [abstract A-15]. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997.
14. 14. Burger DM, Koopmans PP, Brinkman K, et al. Therapeutic drug monitoring of the HIV-protease inhibitor indinavir [abstract A-19]. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington. DC: American Society for Microbiology, 1997.
15. 15. Fiske WD, Benedek LH, White SJ, et al. Pharmacokinetic interaction between efavirenz and nelfinavir mesylate in normal volunteers [abstract 349] In: 5th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA; Foundation for Retrovirology and Human Health, 1998.
16. 16. Murphy RL, Sommadossi JP, Lamson M, Hall DB, Myers M, Dusek A. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J Infect Dis 1999; 179:1116-23.
17. 17. Partaledis JA, Yamaguchi K, Tisdale M, et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995; 69:5228-35.
18. 18. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 1997; 41:1094-8.
19. 19. Calvez V, Yvon A, Tamalet C. et al. Phenotypic resistance and viral load response to abacavir in multi-experienced HIV-1-infected patients (CNAB 3008 French Cohort) [abstract P7]. In: 4th International Congress on Drug Therapy in HIV Infection (Glasgow). AIDS 1998; 12(Suppl4):S9.